Results 1 to 10 of about 27,975 (180)
Ursodeoxycholic acid for treatment of cholestasis in patients with hepatic amyloidosis [PDF]
Vojnosanitetski Pregled, 2009 Background. Amyloidosis represents a group of different diseases characterized by extracellular accumulation of pathologic fibrillar proteins in various tissues and organs.
Faust Dominik +3 more
doaj +3 more sources
Bile Acid Receptor Therapeutics Effects on Chronic Liver Diseases [PDF]
, 2020 In the past ten years, our understanding of the importance of bile acids has expanded from fat absorption and glucose/lipid/energy homeostasis into potential therapeutic targets for amelioration of chronic cholestatic liver diseases.
Alpini, Gianfranco +4 more
core +1 more source
Predicting sinusoidal obstruction syndrome after allogeneic stem cell transplantation with the EASIX biomarker panel [PDF]
, 2020 No biomarker panel is established for prediction of sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD), a major complication of allogeneic stem cell transplantation (alloSCT).
Blau, Igor W. +10 more
core +3 more sources
Journal of Lipid Research, 1998 5-Aminosalicylic acid conjugate of ursodeoxycholic acid was synthesized in above 90% yield by adding a basic solution of 5-aminosalicylic acid into the mixed anhydride formed with ursodeoxycholic acid and ethyl chloroformate.
Ashok K. Batta +4 more
doaj +1 more source
Low-dose ursodeoxycholic acid prolongs cholesterol nucleation time in gallbladder bile of patients with cholesterol gallstones [PDF]
, 1989 The high rate of stone recurrence represents a drawback of non-surgical therapy of cholesterol gallstone disease. Although most studies report that long-term bile acid treatment does not have protective effects, preliminary results suggest that low-dose ...
Brenner, Gerhard +3 more
core +1 more source
Journal of Lipid Research, 1989 We have studied the effect of ursodeoxycholic acid on the serum and urinary bile acids in seven patients with moderate to severe primary biliary cirrhosis.
A K Batta +5 more
doaj +1 more source
Tauroursodeoxycholic acid exerts anticholestatic effects by a cooperative cPKC alpha-/PKA-dependent mechanism in rat liver. [PDF]
, 2008 Objective: Ursodeoxycholic acid (UDCA) exerts anticholestatic effects in part by protein kinase C (PKC)-dependent mechanisms. Its taurine conjugate, TUDCA, is a cPKCa agonist.
Beuers, U. +5 more
core +1 more source
Journal of Lipid Research, 1990 Guinea pig gallbladder bile contains chenodeoxycholic acid (62 +/- 5%), ursodeoxycholic acid (8 +/- 5%), and 7-ketolithocholic acid (30 +/- 5%). All three bile acids became labeled to the same specific activity within 30 min after [3H]cholesterol was ...
GS Tint +5 more
doaj +1 more source
Obeticholic acid for the treatment of primary biliary cholangitis in adult patients: clinical utility and patient selection. [PDF]
, 2016 Primary biliary cholangitis (PBC), previously known as primary biliary "cirrhosis", is a rare autoimmune liver disease characterized by the hallmark autoantibodies to mitochondrial antigens and immune-mediated destruction of small bile duct epithelial ...
Bowlus, Christopher L
core +3 more sources
Journal of Lipid Research, 1978 Twenty-three patients with gallstones were treated with two dosage levels of ursodeoxycholic acid, 600 mg/day and 150 mg/day. Two to three months after the treatment, the molar percentage of cholesterol in bile significantly decreased (from 7.4 to 4.5 ...
I Makino, S Nakagawa
doaj +1 more source